Survodutide

Survodutide is an investigational dual agonist of the glucagon receptor and GLP-1 receptor, developed to combine appetite, glucose, energy-expenditure, and hepatic-metabolic effects into one long-acting peptide program. Preclinical work describes BI 456906 as an acylated peptide designed for once-weekly dosing and shows dual receptor engagement in cell and animal models ^[1]. Human studies have moved beyond early pharmacology: phase 2 trials reported dose-related weight loss in adults with obesity, HbA1c and weight reductions in type 2 diabetes, and histologic MASH improvement in adults with biopsy-confirmed MASH and fibrosis ^[3][4][5]. More recent phase 3 trials reported body-weight reduction in obesity and reduced MRI-measured liver fat in obesity with at-risk MASLD ^[7][8]. The evidence base is clinically meaningful but still developing. Safety findings are dominated by gastrointestinal adverse events, especially during dose escalation, and long-term cardiovascular, hepatic-outcome, and approval-context questions remain. This page should treat survodutide as research/investigational content, not medical advice or a recommendation.

Dual GCGR/GLP-1R Mechanism

Survodutide is designed to activate both glucagon and GLP-1 receptor pathways. Preclinical work supports dual target engagement and suggests that weight effects may involve both reduced food intake and increased energy expenditure, but those mechanistic details come largely from animal and assay models ^[1].

Body Weight and Glycemic Research

In human obesity studies, phase 2 and phase 3 trials reported greater body-weight reduction with survodutide than placebo ^[4][7]. A separate phase 2 trial in people with type 2 diabetes reported reductions in HbA1c and body weight over 16 weeks, supporting metabolic activity in humans while leaving longer-term outcomes unresolved ^[3].

Liver Fat and MASH/MASLD Signals

In biopsy-confirmed MASH with fibrosis, a phase 2 trial reported higher rates of MASH improvement without worsening fibrosis versus placebo ^[5]. A phase 3 MASLD trial later reported reductions in MRI-PDFF liver fat and body weight in adults with obesity and at-risk MASLD, but the trial was limited to 48 weeks and did not establish long-term liver-outcome benefit ^[8].

Investigational Status

Survodutide should be described as investigational research content, not as an approved treatment or medical advice. The major human sources are clinical trials, including phase 2 and phase 3 studies, rather than product labels for routine clinical use ^[4][5][7][8].

Gastrointestinal Tolerability

Across obesity and MASH/MASLD trials, nausea, diarrhea, vomiting, and related gastrointestinal events were among the most common adverse events, especially during dose escalation ^[4][5][7][8]. These tolerability findings are central to any conservative summary.

Population and Duration Limits

The clinical data are strongest for studied trial populations: adults with obesity, type 2 diabetes, MASH, MASLD, or cirrhosis cohorts under protocol conditions ^{[3][5][6][7][8]}. Results should not be generalized to unsupervised use, different dosing, or populations excluded from trials.

Liver and Cirrhosis Context

A phase 1 cirrhosis study evaluated pharmacokinetics and tolerability, but this does not establish efficacy for cirrhosis or broad hepatic safety ^[6]. MASH/MASLD findings remain trial-specific and require longer-term outcome confirmation ^[5][8].